On June 18, 2020, the Food and Drug Administration granted accelerated approval to tazemetostat (TAZVERIK, Epizyme, Inc.), an EZH2 inhibitor, for adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. Read more HERE
On June 22, 2020, the Food and Drug Administration granted accelerated approval to selinexor (XPOVIO, Karyopharm Therapeutics) for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy. Learn more
Relapsed or refractory diffuse large B-cell lymphoma (RR DLBCL) Treatment Protocol Assessment
Shelton, CT June 2020 – Oncolytics Today announced it has applied for business publication membership in BPA Worldwide. Oncolytics Today is published by the National Community Oncology Dispensing Association, Inc. (NCODA) (Cazenovia, NY).
BPA Worldwide will analyze Oncolytics Today’s circulation size – including print and digital editions – source make-up, demographics and geographic coverage. The magazine will have 12 months to complete its initial circulation audit.
NCODA Founder and Executive Director, Michael Reff, RPh, MBA said, “NCODA is committed to producing the highest quality publication for our medically integrated oncology practice community. Working with BPA Worldwide will allow us to continue our Mission while strenghtening the Oncolytics Today brand, providing full transparency in the publication process.”
“We are pleased that Oncolytics Today has applied for business membership in BPA Worldwide,” said BPA President and CEO Glenn Hansen. “We applaud the publisher for providing advertisers and prospects with the solid assurance of an independent circulation audit conducted according to our world-respected, uncompromising standards. With a BPA audit, media buyers can be confident that circulation claims are accurate, and that they have the verified data that they need to assess a publication’s effectiveness in serving its market.”
READ THE FULL PRESS RELEASE HERE
Written by: Andrew Ruplin, PharmD, Seattle Cancer Care Alliance
The purpose of this PQI is understand the management techniques and interventions when utilizing enfortumab vedotin. Continue reading Enfortumab Vedotin management for advanced or metastatic urothelial carcinoma
HORSHAM, Pa., May 1, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approved DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj), a new subcutaneous formulation of daratumumab. DARZALEX FASPRO™ is approved in four regimens across five indications in multiple myeloma patients, including newly diagnosed, transplant-ineligible patients as well as relapsed or refractory patients. As a fixed-dose formulation, DARZALEX FASPRO™ can be administered over approximately three to five minutes, significantly less time than DARZALEX®, which is given intravenously over hours. In the Phase 3 COLUMBA study supporting the approval, DARZALEX FASPRO™ demonstrated a consistent overall response rate (ORR) and pharmacokinetics and a similar safety profile compared with intravenous DARZALEX® in patients with relapsed or refractory multiple myeloma. In addition, there was a nearly two-thirds reduction in systemic administration-related reactions (ARRs) for DARZALEX FASPRO™ compared to intravenous DARZALEX® (13 percent vs. 34 percent, respectively).
Read the full NEWS RELEASE HERE